Latest news from the FASST trial
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
Read latest newsletter on the research: FASST Newsletter, May2016
news & events
Protect yourself to protect us! This is the 2020 World Scleroderma Day campaign by FESCA
The COVID-19 pandemic forced us to redefine our campaign message and to highlight the importance of protecting patients with scleroderma.
The winner of this year is diagnosed with scleroderma. Read her essay here.